Table 2.
Blood analysis and haemogram after treatment with Darmocare Pre® or the placebo. GOT: glutamic oxaloacetic transaminase; GPT: glutamic-pyruvate transaminase; HDL: high-density lipoproteins; LDL: low-density lipoproteins; TNF: tumor necrosis factor α.
| Variable | Placebo Group (n = 22) | Darmocare Pre® (n = 28) | p Value |
|---|---|---|---|
| Leukocytes (×103/µL) | 7.6 ± 0.5 | 7.7 ± 0.8 | 0.92 |
| Neutrophils (×103/µL) | 4.5 ± 0.2 | 4.6 ± 0.3 | 0.79 |
| Lymphocytes (×103/µL) | 2.2 ± 0.2 | 2.3 ± 0.1 | 0.64 |
| Monocytes (×103/µL) | 0.61 ± 0.04 | 0.55 ± 0.03 | 0.23 |
| Eosinophils (×103/µL) | 0.22 ± 0.04 | 0.22 ± 0.05 | 0.88 |
| Basophils (×103/µL) | 0.03 ± 0.01 | 0.03 ± 0.01 | 1.00 |
| Platelets (×103/µL) | 220 ± 28 | 225 ± 36 | 0.92 |
| Erythrocytes (×106/µL) | 5.0 ± 0.6 | 4.8 ± 0.7 | 0.83 |
| Haemoglobin (g/dL) | 12.8 ± 1.3 | 12.9 ± 1.1 | 0.95 |
| Glucose (mg/dL) | 95 ± 11 | 92 ± 10 | 0.84 |
| Urea (mg/dL) | 44 ± 5 | 40 ± 3 | 0.48 |
| GOT (U/L) | 28 ± 3 | 27 ± 4 | 0.85 |
| GPT (U/L) | 25 ± 2 | 24 ± 4 | 0.84 |
| HDL cholesterol (mg/dL) | 46 ± 6 | 44 ± 7 | 0.83 |
| LDL cholesterol (mg/dL) | 120 ± 9 | 126 ± 11 | 0.69 |
| Triglycerides (mg/dL) | 131 ± 21 | 122 ± 16 | 0.73 |
| Total proteins (g/dL) | 7.5 ± 0.4 | 7.4 ± 0.5 | 0.88 |
| Creatinine (mg/dL) | 0.71 ± 0.10 | 0.74 ± 0.15 | 0.88 |
| Calcium (mg/dL) | 8.6 ± 1.0 | 8.9 ± 0.8 | 0.81 |
| Sodium (mEq/L) | 140 ± 3 | 141 ± 3 | 0.82 |
| Potassium (mEq/L) | 4.7 ± 0.8 | 4.8 ± 0.5 | 0.91 |
| C-reactive protein (mg/L) | 4.8 ± 1.5 | 4.9 ± 1.8 | 0.97 |
| TNF-α (pg/mL) | 1.8 ± 0.2 | 2.0 ± 0.3 | 0.60 |